13F-HR filed by ABG Innovation Capital Partners III GP Ltd
ABG Innovation Capital Partners III GP Ltd filed this 13F-HR for the quarter ended 2021-03-31, filed 2021-05-17, with 7 holding rows worth $203,505,000.
- Accession
- 0000950123-21-006752
- Filer
- CIK 1845297
- Filed
- 2021-05-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2021
A holdings report, 7 entries on the cover page, a total value of $203,505,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $203,504,000 with VALUE read as thousands by filing date, 13F file number 028-20837. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFan Yu 028-20833
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ATEA PHARMACEUTICALS INC | 04653R106 | COM | 2,639,178 | $162,969,000 | thousands by filing date | |
| PULMONX CORP | 745848101 | COM | 833,333 | $38,117,000 | thousands by filing date | |
| GENOCEA BIOSCIENCES INC | 372427401 | COMMON STOCK | 375,000 | $1,016,000 | thousands by filing date | |
| SYNLOGIC INC | 87166L100 | COM | 205,906 | $737,000 | thousands by filing date | |
| AERPIO PHARMACEUTICALS INC | 00810B105 | COM | 400,000 | $516,000 | thousands by filing date | |
| NABRIVA THERAPEUTICS PLC | G63637113 | SHS | 45,849 | $76,000 | thousands by filing date | |
| IDERA PHARMACEUTICALS INC | 45168K405 | COM PAR | 56,250 | $73,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-21-006752 | this filing | 2021-05-17 | acceptance time not in the bulk data set |